Respiratory disorder therapies form an important and competitive part of the pharmaceutical market worldwide. There are wide ranges of drugs and therapeutic needs, both acute and chronic. Revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. Our new pharma report - World Respiratory Disorders Market 2009-2024 - will give you the analytical information that you need to understand current trends and likely future events in this market area.

The years 2009 to 2015 will represent a period of high volatility in the respiratory therapeutics market, as important products face patent expiry and new drugs reach the market. What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market? Has the market reached saturation? Where do the opportunities really lie, and what are the main threats in this market? What are the crucial market drivers and restraints? This new report covers these and many other questions for respiratory therapies.

In particular, World Respiratory Disorders Market 2009-2024 discusses prospects for the following product types:

• Combination drugs (Advair/Seretide, Symbicort and Combivent)
• Corticosteroids (Pulmicort, Nasonex/Asmanex and Flovent/Flixotide)
• Leukotriene inhibitors (Singulair)
• Beta-2 agonists (Xopenex, Salamol and Ventolin)
• Antihistamines (Clarinex/Aerius, Allegra/Telfast and Zyrtec)
• Monoclonal antibodies (Synagis and Xolair)
• Other products (Spiriva, Prevnar, Tamiflu and influenza vaccines).

Comprehensive analysis of the respiratory market area

World Respiratory Disorders Market report examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 70 tables and figures, 15 chapters and two interviews with experts. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Why you should buy World Respiratory Disorders Market 2009-2024

By buying this report you will receive the following benefits:

• You will receive a review of the existing market for respiratory disorder therapeutics
• You will receive overall revenue forecasts from 2009 to 2024, at market and sub-market level
• You will find out where leading products and companies are heading, with detailed sales forecasts from 2009 to 2024
• You will receive forecast revenues for leading geographical markets
• You will receive expert opinions from original research interviews
• You will receive well-informed analyses of market drivers and restraints, including SWOT analysis for the sector
• You will receive important pipeline information, seeing how present R&D is shaping the future in that market area.

Respiratory disorder drugs hold the potential for further high revenues. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.


TABLE OF CONTENTS

1 Executive Summary

1.1 Aims of this Report
1.2 Brief Overview of the Chapters

2 Respiratory Diseases

2.1 Overview
2.2 Asthma
2.2.1 Causes and Triggers of Asthma
2.2.2 Increasing Prevalence
2.2.3 High Economic Costs
2.2.4 Treatments for Asthma
2.2.5 Delivery Method - the Inhaler
2.3 Chronic Obstructive Pulmonary Disease (COPD)
2.3.1 Symptoms of COPD
2.3.2 Management of COPD
2.3.3 COPD on the Rise
2.3.4 The Economic Burden of COPD
2.4 Upper Respiratory Infections
2.4.1 Cold
2.4.2 Influenza
2.4.3 Sinusitis
2.4.4 Pharyngitis/Tonsillitis
2.4.5 Allergic Rhinitis
2.5 Major Drug Classes in Treating Respiratory Diseases
2.5.1 Combination Drugs
2.5.2 Leukotriene Inhibitors
2.5.3 Corticosteroids
2.5.4 Beta-2 (Adrenoreceptor) Agonists
2.5.5 Antihistamines
2.5.6 Monoclonal Antibodies

3 World Market 2009-2024

3.1 Summary of Key Findings
3.2 Leading Company: GlaxoSmithKline
3.3 World Sales for Respiratory Disorder Drugs, 2009-2024
3.3.1 Combination Drugs: The Most Successful Category
3.3.2 Corticosteroids
3.3.3 Antihistamines Face Major Challenges
3.3.4 Leukotriene Inhibitors: the Dominance of Singulair
3.3.5 Beta-2 Agonists: the Safety Concerns
3.3.6 Monoclonal Antibodies: Safe from Patent Expiry?
3.4 Increased Competition

4 Combination Drugs: The World Market 2009-2024

4.1 Leading the Market
4.2 GlaxoSmithKline's Advair/Seretide
4.2.1 Three Major Challenges
4.3 Symbicort: Facing Strong Competition
4.3.1 Aiming for a New Market
4.3.2 The COPD Indication
4.3.3 The SMART Concept
4.4 Combivent: Will It Reach Blockbuster Status?
4.5 Will the Leading Position Last?

5 Corticosteroids: The World Market 2009-2024

5.1 AstraZeneca's Pulmicort Leads the Market
5.1.1 Delivery Methods
5.1.2 Challenges for Pulmicort: Are They Insurmountable?
5.2 Nasonex/Asmanex on the Rise
5.3 Flovent/Flixotide - Reached its Peak?
5.4 Will Sales of Corticosteroids Continue to Increase?

6 Leukotriene Inhibitors: The World Market 2009-2024

6.1 Singulair
6.1.1 Competitors from Other Drug Categories
6.1.2 Side Effects

7 Beta-2 Agonists: The World Market 2009-2024

7.1 Sepracor's Xopenex at the Top
7.1.1 Challenges and Competitors
7.2 Teva's Salamol and GlaxoSmithKline's Ventolin
7.3 Safety Issues and Potential Loss of Market Share
7.4 Summary

8 Antihistamines: The World Market 2009-2024

8.1 Clarinex/Aerius Leads the Market
8.1.1 Challenges for Clarinex
8.2 Sanofi-Aventis' Allegra/Telfast
8.2.1 Competition and OTC Availability
8.3 Zyrtec and Patent Expiry
8.4 The Future for Antihistamines

9 Monoclonal Antibodies: The World Market 2009-2024

9.1 Synagis: the Sole Blockbuster?
9.1.1 Numax: A Follow-On Product
9.2 Xolair Shows Steady Growth
9.3 Biologicals vs. Chemically-Derived Pharmaceutical Products: the Advantages of Biologicals
9.4 A Promising Future

10 Other Key Products: The World Market 2009-2024

10.1 Boehringer Ingelheim's Spiriva
10.1.1 Safety Concerns and the UPLIFT Trial
10.1.2 Competition and Other Restraints
10.2 Wyeth's Prevnar
10.2.1 Competition and Development
10.3 Roche's Tamiflu
10.3.1 The Avian Flu Scare
10.3.2 Consequences of the 2009 Swine Flu Outbreak
10.3.3 Competition for Tamiflu
10.4 Influenza Vaccines

11 SWOT Analysis of the Respiratory Market

11.1 Principal Drivers for Respiratory Therapeutics
11.1.1 Expanding Patient Populations
11.1.2 High Economic Cost of Respiratory Diseases
11.1.3 Changing Views of Respiratory Disorders
11.1.4 Educating the Masses: Understanding the Severity of Respiratory Diseases
11.1.5 Management Rather than Cure
11.1.6 Lifecycle Management Strategies to Counter Patent Expiry
11.1.7 Brand Awareness
11.2 Principal Restraints for Respiratory Therapeutics
11.2.1 The Threat of Generics
11.2.2 Restrictions on Healthcare Costs Favour the Use of Generics
11.2.3 Purchasers Hold Increased Bargaining Power
11.2.4 Maturation of the Overall Market – How Much of a Challenge?
11.3 Summary of Market Drivers and Restraints

12 Geographical Breakdown of the Market

12.1 USA
12.2 Europe
12.3 Emerging markets
12.3.1 Russia
12.3.2 China
12.3.3 India

13 The Respiratory Pipeline
13.1 The Lucrative COPD Market
13.1.1 Products to Watch
13.2 Early Assessment of Asthma
13.3 Biologicals
13.3.1 Monoclonal Antibodies
13.3.2 Products to Watch
13.4 Influenza Treatments
13.4.1 Towards a Universal Influenza Vaccine
13.4.2 Products to Watch

14 Expert Opinions

14.1 Dr Janice Reichert
14.1.1 The Threat of Biosimilars
14.1.2 Further Developmental Trends
14.2 Dr Michael Watson
14.2.1 Influenza Vaccines Containing M2e
14.2.2 The Threat of Mutation

15 Conclusions

15.1 High Revenues
15.2 Potential for Growth in Emerging Markets
15.3 Potential for Growth Through Addressing Unmet Needs
15.4 Will Combination Drugs Continue to Dominate?
15.5 Future Opportunities for Monoclonal Antibodies
15.6 The Road Ahead

List of Tables

Table 2.1 Respiratory Diseases
Table 2.2 Causes of Asthma
Table 2.3 Asthma Triggers
Table 2.4 Symptoms of COPD
Table 2.5 Leading Causes of Death, 2004 and 2030
Table 2.6 Symptoms for Upper Respiratory Infections
Table 2.7 Month, Year, and Country of Human Avian Flu Cases, January 08-March 09
Table 3.1 Market Share (%) of the Leading Companies in the Respiratory Therapeutic Area, 2008
Table 3.2 Sales ($m) for the World Respiratory Disorder Market, 2009-2024
Table 3.3 Drug Categories, World Sales ($m) and Market Share (%), 2008 and 2014
Table 3.4 Key Products in the Respiratory Disorder Therapeutic Area, World Sales ($m) and Market Share (%), 2008
Table 4.1 Combination Drugs, Key Products World Sales ($m), 2008-2014
Table 4.2 Combination Drugs, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 5.1 Corticosteroids, Key Products World Sales ($m), 2008-2014
Table 5.2 Corticosteroids, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 6.1 Leukotriene Inhibitors, World Sales ($m), 2008-2014
Table 6.2 Leukotriene Inhibitors, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 7.1 Beta-2 Agonists, Key Products World Sales ($m), 2008-2014
Table 7.2 Beta-2 Agonists, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 8.1 Antihistamines, Key Products World Sales ($m), 2008-2014
Table 8.2 Antihistamines, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 9.1 Monoclonal Antibodies, Key Products World Sales ($m), 2008-2014
Table 9.2 Monoclonal Antibodies, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 10.1 Other Key Products, World Sales ($m), 2008-2014
Table 10.2 Symptoms of Swine Flu
Table 10.3 Influenza vaccines, World Sales ($m), 2008-2014
Table 10.4 Influenza Vaccines, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 11.1 SWOT Analysis for the Respiratory Market, 2009
Table 12.1 Sales ($m), CAGR (%) and Market Share (%) for Key Geographical Markets, 2008, 2014, 2019 and 2024

List of Figures

Figure 3.1 Market Share (%) of the Leading Companies in the Respiratory Therapeutic Area, 2008
Figure 3.2 Sales ($m) for the World Market, 2009-2024
Figure 3.3 Market Share (%) of Key Drug Categories in the Respiratory Market, 2008
Figure 4.1 Sales ($m) for Combination Drugs, 2008-2024
Figure 4.2 Sales ($m) for Advair/Seretide, 2008-2024
Figure 4.3 Key Products Marked Share (%) Within the Combination Drug Category, 2008
Figure 4.4 Sales ($m) for Symbicort, 2008-2024
Figure 4.5 Sales ($m) for Combivent, 2008-2024
Figure 4.6 Sales ($m) of Key Products in the Combination Drug Category, 2009, 2014, 2019 and 2024
Figure 5.1 Sales ($m) for Corticosteroids, 2008-2024
Figure 5.2 Key Product Market Share (%) within the Corticosteroid Category, 2008
Figure 5.3 Sales ($m) for Pulmicort, 2008-2024
Figure 5.4 Sales ($m) for Nasonex, 2008-2024
Figure 5.5 Sales ($m) for Flovent, 2008-2024
Figure 5.6 Sales ($m) of Key Products in the Corticosteroid Category, 2009, 2014, 2019 and 2024
Figure 6.1 Sales ($m) for Leukotriene Inhibitors, 2008-2024
Figure 6.2 Leukotriene Inhibitors, Market Share (%), 2008
Figure 6.3 World Sales ($m) of Singulair, 2008-2024
Figure 6.4 Sales ($m) of Key Products in the Corticosteroid Category, 2009, 2014, 2019 and 2024
Figure 7.1 Sales ($m) for Beta-2 Agonists, 2008-2024
Figure 7.2 Key Products Marked Share (%) Within the Beta-2 Agonist Category, 2008
Figure 7.3 Sales ($m) of Xopenex, 2008-2024
Figure 7.4 Sales ($m) of Salamol, 2008-2024
Figure 7.5 Sales ($m) of Ventolin, 2008-2024
Figure 7.6 Sales ($m) of Key Products in the Beta-2 Agonists Category, 2009, 2014, 2019 and 2024
Figure 8.1 Sales ($m) for Antihistamines, 2008-2024
Figure 8.2 Antihistamines Market Share (%), 2008
Figure 8.3 Sales ($m) for Clarinex, 2008-2024
Figure 8.4 Sales ($m) for Allegra, 2008-2024
Figure 8.5 Sales ($m) for Zyrtec, 2008-2024
Figure 8.6 Sales ($m) of Key Products in the Antihistamine Category, 2009, 2014, 2019 and 2024
Figure 9.1 Sales ($m) for Monoclonal Antibodies, 2008-2024
Figure 9.2 Key Product Market Share (%) within the Monoclonal Antibody Category, 2008
Figure 9.3 Sales ($m) for Synagis, 2008-2024
Figure 9.4 Sales ($m) of Key Products in the Monoclonal Antibody Category, 2009, 2014, 2019 and 2024
Figure 9.5 Sales ($m) for Xolair, 2008-2024
Figure 10.1 Sales ($m) for Spiriva, 2008-2024
Figure 10.2 Sales ($m) for Prevnar, 2008-2024
Figure 10.3 Sales ($m) for Tamiflu, 2008-2024
Figure 10.4 Sales ($m) for Influenza Vaccines, 2008-2024
Figure 12.1 Market Share (%) for Key Geographical Regions, 2008
Figure 12.2 Sales ($m) for the Respiratory Markets in the US, Europe and E7 Countries, 2009, 2014, 2019 and 2024

Companies Listed

American Academy of Allergy, Asthma & Immunology
American Thoracic Society
Apotex
Applied Molecular Evolution
Arrow Group Ltd
AstraZeneca
Biocryst
Boehringer Ingelheim
Breath Limited
British Lung Foundation
Centers for Disease Control and Prevention
Centers for Medicare and Medicaid Services
Chugai
Cipla
Daiichi Sankyo
Dr. Reddy's
Eli Lilly
European Medicines Agency
European Patent Office
Food and Drug Administration
Genentech
GeoPharm
GlaxoSmithKline
Hetero Drugs
Johnson & Johnson
Kyorin
MedImmune
Merck & Co
Mylan Inc
National Heart, Lung and Blood Institute
Novartis
Nycomed
Ono Pharmaceuticals
Orchid Pharmaceuticals
Perrigo
Pfizer
Ranbaxy
Roche
Sandoz
Sanofi-Aventis
Schering-Plough
Sepracor
Shanghai Pharmaceuticals
SkyePharma
Tanox Biosystems
Teva Pharmaceutical Industries
Theravance Inc
US Centers for Disease Control
World Health Organisation
Wyeth